Jasper Therapeutics, Inc. Stock price

Equities

JSPR

US4718712023

Pharmaceuticals

Delayed Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
29.36 USD +1.87% Intraday chart for Jasper Therapeutics, Inc. -1.04% +272.12%
Sales 2024 * - Sales 2025 * 7.33M Capitalization 442M
Net income 2024 * -71M Net income 2025 * -74M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 60.3 x
P/E ratio 2024 *
-5.9 x
P/E ratio 2025 *
-7.47 x
Employees 45
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.22%
More Fundamentals * Assessed data
Dynamic Chart
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating MT
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise MT
Jasper Therapeutics, Inc. Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation At ASH 2023 CI
Jasper Therapeutics Says First Patient Dosed in Phase 1b/2a Trial of Briquilimab for CSU Treatment MT
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1B/2A Clinical Study of Briquilimab in Chronic Spontaneous Urticaria CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant at ASH 2023 CI
Jasper Therapeutics, Inc. Announces Board Changes CI
Transcript : Jasper Therapeutics, Inc. - Special Call
Jasper Therapeutics Appoints Herb Cross as CFO MT
More news

Latest transcript on Jasper Therapeutics, Inc.

1 day+1.87%
1 week-1.04%
Current month+38.16%
1 month+46.80%
3 months+308.97%
6 months+332.27%
Current year+272.12%
More quotes
1 week
26.89
Extreme 26.8913
31.00
1 month
20.62
Extreme 20.6201
31.00
Current year
6.41
Extreme 6.41
31.00
1 year
4.00
Extreme 4
31.00
3 years
3.86
Extreme 3.862
188.80
5 years
3.86
Extreme 3.862
188.80
10 years
3.86
Extreme 3.862
188.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 22-03-14
Director of Finance/CFO 52 23-09-21
Chief Tech/Sci/R&D Officer - 19-12-31
Members of the board TitleAgeSince
Chief Executive Officer 62 22-03-14
Chairman 72 Oct. 31
Director/Board Member 56 21-09-23
More insiders
Date Price Change Volume
24-03-28 29.36 +1.87% 95,945
24-03-27 28.82 +3.33% 69,788
24-03-26 27.89 +0.69% 80,735
24-03-25 27.7 -5.23% 135,009
24-03-22 29.23 -1.48% 55,779

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
29.36 USD
Average target price
63.75 USD
Spread / Average Target
+117.13%
Consensus
  1. Stock
  2. Equities
  3. Stock Jasper Therapeutics, Inc. - Nasdaq